<SEC-DOCUMENT>0001193125-13-452091.txt : 20131125
<SEC-HEADER>0001193125-13-452091.hdr.sgml : 20131125
<ACCEPTANCE-DATETIME>20131125061000
ACCESSION NUMBER:		0001193125-13-452091
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131125
FILED AS OF DATE:		20131125
DATE AS OF CHANGE:		20131125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131239551

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d634185d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other
document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under
the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security
holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Novogen Limited </B>(Registrant)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Andrew Bursill</U></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andrew Bursill</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Secretary</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date 25&nbsp;November 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(ASX: NRT)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g634185tx003.jpg" ALT="LOGO">
&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25&nbsp;November 2013 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Announces That CanTx Drug
Destroys Ovarian Cancer Stem Cell Spheroids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25&nbsp;November 2013, Sydney, Australia:</B> Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN)
today reported that its US subsidiary, CanTx, has found that lead drug candidate Trilexium is highly effective at destroying ovarian cancer spheroid architecture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group Chief Scientific Officer, Dr David Brown, said today, &#147;This result is a important step forward in predicting the likely success of
Trilexium in vivo and in the clinic in particular. Spheroids are mini-tumors and the ability of Trilexium to penetrate and to kill these tumor cell structures is a significant step forward for this drug.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Researchers at Yale University have shown that cancer stem cells isolated from the tumors of ovarian cancer patients are able to form self-renewing spheroids,
regarded as a 3-dimensional model of ovarian cancer in the test tube. When injected into a mouse model, these spheroids form highly vascularized tumors mirroring that of the human disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Gil Mor of Yale Medical School said, &#147;In terms of drug discovery, these 3-dimensional structures serve as a robust screen to identify drug
candidates worth progressing into expensive animal studies. They come directly from drug-resistant tumors and standard-of-care drugs such as paclitaxel and carboplatin have no effect on them&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Trilexium is the first drug in our hands that has been shown to penetrate and destroy the spheroid architecture,&#148; Dr Mor added. &#147;This
observation demonstrates that Trilexium can diffuse into the spheroid and gives us confidence that it should be able to kill ovarian cancer tumors in vivo&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Novogen CEO, said, &#147;We propose to deliver Trilexium into the peritoneal cavity where ovarian cancer originates and spreads. By packing
the drug into a highly targeted delivery system, we are able to deliver significant quantities of the drug directly to the usual multiple tumors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ovarian Cancer and ovarian cancer stem cells </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
American Cancer Society estimates that over 22,000 women will be diagnosed with ovarian cancer during 2013 and 14,230 American women will die from the disease. It ranks fifth in cancer deaths among women, accounting for more deaths than any other
cancer of the female reproductive system. Cancer stem cells are thought to be the tumor-initiating cells in many cancers responsible for both the production of the tumor mass and metastasis. Ovarian cancer stem cells have been isolated and
characterized from ovarian cancers. These cells are highly resistant to chemotherapy and radiotherapy, a property thought responsible for tumor recurrence following successful initial therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN 063 259 754 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P: +61 (0)&nbsp;2 9476 0344 - F: +61 (0)&nbsp;2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CanTx </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx Ltd is a private biotechnology company based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is
dedicated to the development of anti-cancer drugs for the treatment of ovarian cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol
&#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Trilexium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trilexium belongs to a new class of drug
candidates known (structurally) as super-benzopyrans. Members of this family of drugs are showing high potency against both cancer stem cells and somatic cancer cells isolated from both ovarian cancers and glioblastoma cancers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact Dr Graham Kelly, Chief
Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: 61 2 9476 0344 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: 61 2 9476 0388
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mobile: (61)&nbsp;0429 854 390 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16-20 Edgeworth David Ave
Hornsby NSW 2077 AUSTRALIA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: Graham.Kelly@novogen.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is
available on the Company&#146;s web site, www.novogen.com and www.can-tx.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g634185tx003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g634185tx003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@#N`P$1``(1`0,1`?_$`-L``0`!!`,!`0$`````
M```````)`P<("@0%!@$+`@$!``$$`P$!``````````````$%!@<(`@,$"0H0
M```&`@(`!`,"!@D&'P````$"`P0%!@<(`!$A$A,),2(4015188$C%PHR,R06
M)C88.!EQL71%ECF1H='A0F+20U,T1%1DE#6EQ4969K;6-[?76'B8*7DZ$0`!
M`P($`P4""`H'"0$````!``(#$00A,04&05$287$B$P<R"(&10E)BTC,4\*'!
M(],TE!4U%M%4154V%QBQX7*"0U-C<Y-&_]H`#`,!``(1`Q$`/P#;F]T?=-CH
MOJ#?\K,7#0V3;$0N.L*1+DQ##)9.M39TA$/CMA$#.(ZILD7$P\*'@9NP,01+
MYP'EJ[SW''M;;\^JNI]X#>F,'Y4C@>G#B!BXCB!3BLN^B'IO-ZG^H%IH+@1I
M,;A-=.QH(6$5;7G*XMC%:>T3P7YRQK)>W1UI"0R=E"2E)%RY?24DYR-=!7D9
M)ZNHZD'[CR3A$P6=NE3J&`I2E`3=``!T'-)[G=&NW,SII;F0O>ZIQY_AGF5]
MF(-A[1AA:QFGV>`I]C'PP^;\2^??MM_.!^__`"2/JI&2.`Y%N_7E.`E-_;[P
M[#G5_,&M8`7,M0:Y_A@NX;(VB"3^[K*I%#^9C^JMW#]7SWF=[#:W2>M62;&Z
MF<RZNI1L,QD)E^N^F[GA.1`4*%8G3MXJJ\D7]8605@GRAA,(%;-%#F$SCH-M
MO2K=O\R;?;;W+JZE:^%WTF_)<.X>$X84&.*^6/O7>E3=B[S&X=)A;'MW4S6C
M!1L=PT5>V@`:T2M_.-`S(DY+8,YE%:I)PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB_/S][?=E3<#<B;H]4DSN\*:LOK!B^H
M(IG,#.;R0DZ39Y8NIDQ.8ASIS$<6$:&Z#IM&F.'7KF`-1?6;=,FK:[^Y("18
MV9I_Q2&G63W9#/`5&9"^NONF>E\.S-A,UZ\:#KNK!L\APJR*A\B,'DUCB\Y^
M.1P&`"B`,``4H)^*?8]#^/[>87=6BVP-`!T>POO@`=\[:@-KP4+)_2O;2?T9
MV=QGLM#'=J057?*0>5H-H?RA:\0V%1NWN\2HF;M-9U&MD4Y1CY@'RR$>B/A\
M>7IZ?;DFVUN6"[%3;R.\N1H^4QQ%>\@X@<P%B;UH]/+#U'V%>Z#=AK;@Q]<,
MA&,<S,8W\Z!WA<.+'/'%?IH5FQPMPKE?MU;?)RE=M,)%6.!DT2J$2D86;8(2
M<6^2(L1-4B;MBZ34*!BE,`&\0`?#F\['MD8)&&K'`$'F#B%\/+JVFLKJ2SN!
MTW$4CF.%0:.:2UPJ,#0@XC!=WSDO.G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(M&K]8-TG#`&S$3M+1X8K3%>T3L[2Y)L$138
MUK.T-'`I)+K@0OHMDLDUUH$@3L0%619/C?YX4.:N^MNT_NE\S<UHT_=I_#+3
M(2#CV=8Q[7!Q7U)]SGU5&XML.V)JTE=7TL`1DYOM7&C.\Q._-N/S3%7Q$DP$
M]&\QT@$!22`#`H'P-W]GXQY@"E1B:+=PAP)8/LVXU3XA\/R<YUZFU4*0+VP-
M+7>]VX-%Q9*M%7&(*%]'E;/#HO::)J)`2:`1U-,MUT#K(MA*E'>0H^K]"#Q4
MO[2)@R5Z6[3&Y]Q-=<@G3;8>8\\#0CI97Z1P/'IJ1DL`>\7ZH1^FGI_<7-O(
M!KEV##:MP)\UX/B(^;&T.D=PJ&MS<`=IS=#W4\C8+SU*81UQJN)9JKXSA8^"
MN<I<(FQNTVUW$H+J5BMIUFS5UBUCJQ#F;H."F34$CLQTBB7T3%Y]%]O;)@U#
M3FW=\^2(.]EK.D>"F&8.>8[*+\VWJ;[P^H;<W7/I&A16UVV$],TDWF.<Z>I\
MT`A[:])\+B:DO#C4BBQ:_IH]Q?\`D)KG_<[D3_Q&Y7?\O='X37%>]GU5CS_5
M)N_^H:;\4WZ99IZ#^Z3?]@LYKX3SW7L<UEW;(%=_BR;HC.P1;60L$&1=[.U:
M<3L=DGO4?/X8!=1YD12\WTBR9BF,=/EO;BV8S2+#[Y:R.D<UWB::8-YB@&1I
M7LQR!63?2WUZNMY[C;H&X(+:V,["(71]8K*/%T.ZWN`#FAW0<"7@,%2\!3?\
ML!;-)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBQ.W@
MU2J&ZNL.5->+<"+4;E!'7J-@,D11Q3\@PIOO2D6UF84U%$U(:?;HF6`G1EFA
MED1'RJFY1]?T:VU_1Y](N@#'-&0#\UV;7#N=0]HJ,BK[]-=\:AZ=;SLMU6!=
M2"4"5@-/,@<0)8SWMQ;6H#PUU#2BT)P]I'W/F9G3%WIKDA9TQ<+,EEXZ;QXY
MBWJS18[=1Y&NQNA!<1SLR?JH'$"F,D8HB`#V`:B3>D.^6S.9%:!T0)Q\R(5'
M#-X*^M%I[S7HW+:,F?K5LQ[F-/2>H$5&1%*M/,'$'`K^E/::]S,B7J)Z6Y5.
M8I#"=,)7'0',8`[`I/-=BE,(_9X]=\X-](M^DT^Y`#GYL7X_&O0_WE_1AK`Y
MNMVI=3*I_H6RIIMB!3V=/;*MF5<FU]C'[9YR=(2\Q7W*S%Z]99!L+-Q%XJQ:
MH\8N';5[&XZAP/(2@(J&2%P,B8IQ*)!#;7T=]/?W/91:;,VMP]WFW+A0GI!H
M&`CD*-'TG..2^2GOL^\5!K=W=:YILH=I5I&;73VX@23R`E\Y%*T!!/(QQ-H0
M7U,(1#R+AP[?33YQ*SDN\>S4]+NU!5=RLU+.E7\K).E3?,HX>OW!U#"/P$W0
M=!T'-OHF1,BK&`&<!R7Q`N)Y+F9TTKBZ1SB22:DDFI)/$DXD\2JWD#\?^%_B
M<Y=78%TJJSEY^LR]=ME/DE82W4VP15JJLPCV"T=8()XE(1KGP_9H"NB!%B?L
M5$3&(/93"`],D$,T4AE:'ND86])RH10_&%[=.OKG3;Z*]M7F.>)[7M<,VN:0
MYI'<0#R.1!!(6Z]JKL'7]H,$T/,<"5)HM88WZ6SP9%045K%SB3?06FN.0\YS
MD-'2J1_2$P]JMCI*_L3@(Z\ZOITFE7[[20'I&+2>+3D?R'M!7U'V%NVUWMM>
MVUZW($KV],K1\B9H`D;QPK1S>;'-/%9#\IBO%.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1=18)Z'JT%-6:PR#>*@:]%2$W-2CLX)-8Z*
MBFBKZ0>N5!\"(-6B!SF'[`+SLABDGE;#$"Z5[@`!Q)P"\M]>VNFV4NH7KQ'9
MP1N>]QR:UH)<3W`+5>N'O`[?V"Z6^9QS*X^K.-G]CDE:!!S-!1E9QG3R+"C!
MGF)%:12.YDW[)(KE?Y"@FHL*8!Y2AS,FG[%TA^G-?<M+KOCXW"O,T!``Y4X<
M\UH-K?O$^H$FKSOTJY9!IKI'&./R(7=#*^!I<]A<YP;3J).+JD!HHT="'NT;
MW"'0W#%Y>S"`'#&+,1Z^P>AE1+\>>K^2-`!^Q.67F2?65*_U">J-?X@S]FMO
MT:IYKS!D/>_5LF2KK*)2&:]-+C)RV1:=6F1XJM6S#>1TTF3#+$=7/JG7HSE*
M<,A9O3)>8B;,CA3Y?4`G/-96L6W=7-O:QAEA=@`%U20]@-6=1J2'-)<*G,$<
ME4]Q[@U7U3V)^]=0G=)K^BR'SF`-8R2UN'-Z;@1MHT/AD:(7]+?LW-<<:J.Y
M-0%"@<IP.4Y2G(("`AY#``EZ$/B'7V\O.K#1S/8R':L`%I::'-?WWR:A%QW:
MZ3=!9=0Y4BH$,L8YA`I02(`F.)A'X``!X\YL#H@V=V,;:U[%`!>>@9E28XEV
M)RC[>6N%#:T9&OR>9]J+(KG.0I606\Z_K&,<,-XHM<J<HI7XJ4@';:XY,<,R
M.P.+GR"T0'SIB9,H\L"^TNVW1J\CY"\6D1Z`YM*%Y-7`''!@H#S<XX^&AV-V
MYO+5?1S:<`MQ')K>JN%P8I0XB*U:TLA>X`MI)<.ZGMY0L;4>,%O=?TS&[(=?
MP8US'S#T`_O-O_@'X1#])/?PX=Z>:87/#9)0`,*D8_B7K_U/[RP/W6Q[NA_Z
M172PA[RF>G.9,>0V>X'"['$%BL#>N6^<I]>N$3/5H)OMA$6,CN5N<['FBHN9
M50%^0S8QOHSJ'*8#$`!IVJ;`BM;`W-I(Y\@:<*CVLZ9#/+L)![%7ML^\QK-W
MKEM;:];VS-*?,ULKF-<'-8[PEX)<[V"0\BAJUKFX$]0V4BF*<I3D,!B&`#%,
M40,4Q3!V4Q3!V`@(#X#S%Y!!H<UN<US7M#V$%I%01B"#Q"PTW8WHPUH3CZJ9
M(S5%Y#EX2Y71"B0K/&]7;VJ9--N(:6G"&<LG,O#)HL090RH"H"IC>H)0`H]B
M(0312KXX'S?CS9'#V/LYXIE59F@9+KC.RUUVZ;"RD$D'/G2=1LLP,=0T?,P[
M]%5H\0$QO1<HG)YC==C**V>6]O\`%.%]AM:M9;>SN:^1=JE<B(XS=0<`C(U9
MF;&4+'SMB&W3)Y)JK"%6:2216GD;N/64[`?(`=\BO!%>;*F5\;8/H-DREEV[
M5S'>/*A'J2=DMUJDD(N&BV:?0`*SA<P"JX74$$T4$P.NNJ8J:9#G,4HRBB-2
M]]?7*Q(24[BC6G??-^/HU1<@93Q=JY893'\BFU2!9TYC9::F8%XHU03'S&.L
MV0#R_,'9!`PQ5159KZ<>X;JMO7$S3G`5^5?6>J(ME;MC*W1#RGY-I8.CF0(:
M>J4L4CD6A'111,[:'=LO5Z*"PB8O:H*E>FU4W/Q%M^.;6>-65V@+!KWF*S8/
MRA4\A0#:NV.%N-8.";ARBS9RLPW>5Z3.54&3LJP>N+=7Y"^7Q`U19;<E%BIA
M;</%&?<Z;+8#QTRNKZQZI3]5J.5+4_KZ+&@&N%KB%IM.JU>?&25=3LS!L4@&
M1+](DDV.<I0.<>^HJBPZRG[TNH-)R7.8>Q;#9WVVR)5'+UC<874S$DOF!C4G
MT><Z3QG,V-J[BJ\JY;K$$BI&3EX*)OVSR^':H45798%]Y/4+->6F&!;*SS+K
M1F6<=HL*OC_:/&,AB64MCYQZ16K"!?N'TM!GD7JROIMFKETV<NE0\B*9S&*!
ME>!2HR4KHB!0$QA```!$1$>@``\1$1'P``#DJ5$%E7WN]*:#DB7Q)CQ+-6TM
M]KCYS&V:)U7Q3*9;90#UF<R+ILZL+=[$5Y^JW7*)#@P=.P(;P,(<BH457LM:
M/=SUQV8SE":WL,;[/X=S'9HZP2];JN=L#V6AIS,95H=S.3CM*<;KSL%'D9,&
MIN@?.&IEE!*FD!SF`O%<:*5WFT/NIX`U2SHCKK;\=;(9$R:M0(W)81>$<//,
MG)DJTG(R<8FY.G%3"$F"C9S%*>OTV%)$IT^S]FZX)HH)HK8TCWG<%7R]T;'\
M=K'[@,1)7ZY5JDQTQ9=2+I"5>'?VB89PK25L\XX?F;PE=CW#TJKUXH`D;-RG
M4,`@4>.I*J\>Z/NBZSZ&W['>/<[M,GA(Y(@G5FC9FETM&RUR#@6$^SKTA)V9
M^,U'N8YNP<O065])!<P-RF,`";H@JI52'QTBPEX]C+13QM(QDHS:R,=(,EDW
M#-\P>H$<LWC1PD8R2[9RW5*=,Y1$IBF`0'H>2I6,%>W$Q/9MPLAZ11[.Z$S'
MC/$56S587SNOI(T1>HVZ4"(BV\59"R2B[N=2<B!EVYFJ92$'L%##X<BN-$KP
M4<'O-[.&KM)KVJ50D13L65FQ;%D]1FH(.(K%\<]\C.&6.3Q14O4ZT%$P=@8S
M!DY*(>54!YD#9.B_>9':I+@R,]+.T_*/P#PCM<<J8ZM>\COPZ;IT6S;!]+FY
M`EN"#E$#^;C-/^X\%[JT\,8%"'FFNX0A44_('0^F!2%+X>`!T`!UX?`.9C/3
M4&/!E%H]4G$JJ'P_!^+G65*N_K[FHVO68JWDIZU&6HZ[=_2,PU<Q/6:6_$%O
M(G&W2&>LQ$$WQF;02OFY#]@+AJ0/`##RE:UISM6LS'">B>+QM=R>W%A':#^(
ME7EL7<SMJZ_'?2-,NG2AT5Q%PFMI1T31$'YS"2WZ;6GA0\78_$C#6W,<]C9.
M=;R5*D&C"]X<M"BY1;6[$5N(:1J$FU=*"4KQ2-;G,P<F#Q%=J)Q\#E$6CZFW
M5;;J,89,P=+F?->W!X^/$=A"Y;YVL_:VNR64+_/TV1K9;>8936\HZH9.\MP=
MR>UPH%93[\AOLF(_O^R4?Z_GZY5O+/%K:=ZLSI=R*R`UAQM6<TY8(E=9!JWP
MKB:!D,Q9]GTU"JM8_&]._=RL`<Y3E*,C=Y%%..01`P**)J+&(`B3E#UJZ;96
MKF6DG5>3.#(V'BY^%>YN+B<J#'DKZV#MR'7=8\[4ZQZ!91FXNWUH6P14+FM-
M1XY32&,`@E[Q0BE1Y++&69[/F4[OF>RH!'O+M*%4A*^0"$;5"E1:)(VF5!BB
MF4B2#:!@&Z*9@(4I3N#*'Z[.//7IUDS3K=ME'C'&T#J^><W./:YU2>TYG-4C
M=FX+G<VO7&L7(#'32$A@]F-@HV.)N5&11AL;<!@W(9#P7Q`0^T0\.5%I:#5V
M2MLY+A.FR+QJLR<)`LFX15;KE,'F`R2I#$.`_;T(#UR1&Q[7Q2FD+\E(>YCA
M(WV@5M4^U#M(MG?`">.KA+?7Y5P,6-IL^JY4\S^PTTS8Y:';U!-\ZZKN,:'8
MNU/$1>L5#F'\X41P;O#1GZ;J)N&MI;3.)'8X4ZO@->H=Y%,,?H9Z![\&Z]K#
M1[QU=7TUK6&IJ7P'")QXU;0QN[&M=6KB!CG[Y\@I&5OV^W:9"*"'N&8)1425
M(15)=NZ"::.6RR2A3D50<MUS)G(8!`Q3"`AT/+0*SN5P]$95WHKOQL7[:UK6
M&/Q!F%S.[;Z/N'1S_0IP%F?JJY>Q!%+JB<QEZ?.$.[;-_,`@W176,'F7*95D
M:*!G0KO=^`_^6SV;/[.VV_[OJAQQ7(JW.S]3:^X1[O..]-,B*GE=8=,<.1>S
M64L<*++$@\H9:M4G'LZ'$VQF5,6\O#U^-E6+DK983$426=D\/.;N#B5'&BV`
MH^/81+%G%Q3)I&QD<U091\='MD6;%BR:I%1;-&;1L1-NU:MT2`1-,A2D(4``
M```YR4K7D]X+&,/J#E?6SW6\*L&--R/CK-E+QOL*E#)C&-,O8DR4]"OR1+8W
M8H^G*2,>03-S.%"BL=%P0XG%1HV$D'#%0<,5[/';QMJI[Y.0*P@J9GBSW,=?
M8C+-5`IU&\6;-V'4#M+#V598J)I28JJ:SA7RE`XG>-B``F.<>./>HR*F&V3S
M?6M:\`YASY;UD4:]B3'EHO#XJYCE(\4@XMPZCXLGI`98[B8DBHM4BD`3G56*
M4H"80#DKDM8F83S?K7[.N'JA`S3VM;A^[GLI"N[U;@=@VLD-*;93BL]/OFS]
M(2*IJQN.4H^)*8@I"W5D#JE*F83=1P[2H/8MEC5;5G#FG6%J=@W"54C*U5ZK
M%,VKQZV9((S-NFTT"ED[9:I`A1<R]@FG7G6556.?TP,"2?E2(0A94JR7N.Z4
MXVW=UDR#C^U0<>%_@Z[+V;#E_3:)EL]!R'"LE9*`?PTND4L@VCY!^U3;/VY#
M^FX;*&^7U2)')!%5!%5!;?M^LVYR]E_5"DP=NEH?9C;;,==T5M%U(#Q"P(_=
M%GD*CD2U(OVISN1G']6C&J<@Y*)3G.]=JIB4P%Z5J$X+8_U:U6PKIWAZJ84P
M;3HNK5BM1;)H]?-V;8D_;I9!(0>VBWRR:174Y/RKI119598Q@3]3TT@(D4B9
M9R4K(@4R&,0YB$,=/S>F<2@)B></*;R&$.R^8O@/7Q#A%!(Z%8OZQ%'G`WD;
M?T=*Y51$P%*8WZ27)RE'L0`WE\@F^WH`[^SD<5'%3L%<(',!"KHF./?1"J$$
MP]!V/10,(CT')4K7S]P:@5;,7N\:(83O;`LK1<QZJ[;X\N,<8I#"YA)RG6(1
M40,<IRHO8]^U0=-U.OS;A`AOLZ&*XT4$55[_`&=,Q7:#IN7_`&],\22[K/\`
MH-;_`-&Z;^0.?ZN_X#DQ4>X5R$Q,N<5GC%6N"1B)P#I-)%MYA\Z@@`<D'XUX
M_$O_`.@_;3_T#83_`.F:/)'%.*Q+]X;7Z7QSL3%;&-%'\E3<Y1\56Y=9TLLZ
M2K&0*3"),&$2@*GF(QB;+5V17#9(!`OUC5V8`[4YEO8^I13Z<[3Y"&R1X=[7
M$D'XR0:=E<3CHM[RNU+NPW-'N5G4ZPOF`5S#)8FM:YA/TF!KV`YT>`2&T;$T
M'9Q.L/R=F[`O7^/]G,C!GD,$(Q[5K'6I57G!2JL?`6*X3E>I%.BAG+A=YZ+J
M56AB`)AD)N<<D9,DS@'?D;)'4]5=0>BI($.<P@4HCSHFG;'!(V9PB@#2XO.0
MH*G\07OTVPN=2U"&RLF.EO)9&L8QN;G/<&M:.TN(`4I&PNR,+K).8XU,QUBK
M77/336C&<-CVXY&SWCP<H3JM^='&;L-=J4BYE6"D/6X-5Z!3M/F(W6/],4"`
MV\O+"TG0KK6HI-4EFN(&2R=0:Q_15M`&N(H:N(%2>-0MD=U^HMEL*:VV3IEA
MI>IG3+9L$D]U#YY,W4Z29L;BYI;$Q[RT-R!#@*`45B/Y>-F_\H^@G_MP0_ZR
M\JG\HGA>7]?_`&_[E:?^>%Q_<&V_V(?75T\?9P>[ATW-.I#S&6"<&7;*52C[
M?B"2P12"8PC<C7[$[U2VHXLR0F63?IV!C9HY!08\ISID2524\#&\@#X)]#GT
M%\>J3SR7#(W],@>XO+(WX&1O(M-.KZ!*KFG;X;ZEZ?>[.%EI^FZC<0>9;&TB
M\CSYX*R"VE\1ZVRM#O*!RG$9SH%&4S6.NF8R[99D\155:/V+E,R+EB^9JG;/
M&+E`X%.BY9NDCIJ$,`&*<H@/CR_F/ZHFM;]F,EKG+&Z*0L?7J!XYKE&$0#L`
M['\'PY/2'>$X+K7SOTQ]0![,H'7E\/#P[_K<XD-NV^2W#HXI[.*FS]E#`UBD
M+WDG:!V\EHFH,H1UA^K,6RZC:/NTH=_'S-JDY!$.BR4;4UV3=JT$0$A7JSGH
M?,D8.8SW_J<;VQZ:*.E!K7DT9'O<3\0/-;<>['M2_-]<[LE+X].CC,+`"0)9
M'T+P>!;&T-)%?;<W#P*Y_OQA_`[V_O\`[$]?NO'KQ^IE?AUS%Q%1\*W+)-0.
M:O7[Q6O%ZO&#J7M;@-H8-HM$KFAL)BE9HD)WMDK<&1-3*6.5R$^9Y&VJI-CJ
M&;B!_7.T!$"F!8Y3"I/-8?Y6V`I>UN\_L)[%8\6]:HY5KNT-E9I"<#JQ$BMC
MFIHSM=>F#H/O*NSC9PQ<!]BR!NO#KCD4*N37YAG@;]8/R<WO"XQ<7NGI]3$\
M42;HI6\?+7+%;B%CIFL(O7"B22DB2'ICE<$4_.H<RZ)0#L_'%.*GTY*E0-?K
M`TTA:M6\-:KP"BC_`"OM;L_AR@T"M,DTW,G(-(BT,I:T3";83E4!G"(J-2G5
M`!*59TD4W0'[Y!4%5?>TH<OBW!6KVZ](1</;I[?&=L:Y`>N$$@(O(XIF7472
MLC,G1TV[@Z;-V@9D9<3=IHMA7/T)@*/!0JK[K5Q:[8H:':'XVEU'\-O7E:J9
M*R.Y8>MZA=5<2M8O*=N?R+<BR(I1]F4!@@B5;R`JHD<I#E5(4!''!,UQ/?5B
M@QMA[3'9-E#KNJ9J'NA@Z_7&)C2)IHQV/PD"Q*[SQ$11;LI!JP:$\I3`3ZL#
M#T4HCP4*G/K\_"VN`A+36Y-I-5VRQ$;/P$S'JE782T+,,D9&+DV2Y?E6:/V+
ME-5,X>!B'`>2I5OL\9/JV%<*Y5RU=I9G"57'=`M5LF9)^J1)NBVAX=V[*B'G
M,7UG+U<A$$$2]J+KJ$3(`G,4!(M-UICR_83]HOVV-OK)#/4H/%&_)-IKE$(1
MSMQ(1&,<N9!F2,IMPD8B14&H(>AZ)C#Y%AD6HE$0/WSCD%Q.6&2W8*W8X*X5
MV!MM7E64[6K1#1EAKTW&K%<QTQ"3+)&1BI1BX)\J[-^Q<IJIG#P,0P#SDN2C
MDW)W'ROK[M_[=>!:/`T63I&V.4+]2\G25E9S;BRPT36:PSEXQ>EKQLS'QS-\
MH\<CZQGC=V0R8`!2E'YN1C5.-%&YLYK;AW;7WU&6&,Z5V3LM$5T*96PC")M-
MEI[L)N'R%+-&;C[VJDG$2ID"-I%8ID?6!,PF`3`(E#CC3L4<5(7A[V9?;_P1
ME>@9LQIBZXP^1,93A[%3Y9]F?+T\S82JD:_B#K.H2<NC^&DTA8R2Q?3<H*I@
M)@-UY@`0=(2BQKVXZ_IU/:V_#^A?9GK^XZU]_DXXIQ5#W0H:6TQV8UP]V2@L
M70UNDO(W7;=2(B$3">QZ\WV70;0EUD$$2E([=XWLJZ9RJJB(]F:%$032$Q!S
MJA7$Q/;:P'ON[8Y"&=C`I)_;APG<"6@72?W*-6+8TY@9\'W?HC%_=7[H]7OR
M^E\W?7'%.*ENVHU^KVS^";]ANP"FU/8XL5ZU-&3*=:LW*+-]?5K&U$2F,12,
MET4S*`7H5&YE$_@<>5/2;]VFW[+H5+`:.'-IS'Y1V@*T-^;4M]Z;6NM!FH)G
MLZHG'Y$S,8W=U?"[FQSAQ6D3,J.Z;8)^CWOT*_=*5.RM3ML,[6*DXC+!!/%&
M$DW$J@@8R)ET1.D?KI1(Q3AV!@'FPUI=V\]FVZ:\.<ZE!S!R/<1BOEUJ.F7F
MG7\MA<QNCGB>YKFG-KFDM<TY8M<"#4#$9!<(;77`_MS'_P"V4O\`-\]'0XXT
M7B\N3E_L4ANG)HC!V*<L>X+8VK23<U1.0PMJQ$/`!1M9,TV=HHREK4W3'Y73
M"JLC'0,H4!*"*<AT8%$P$MF[AN)=0O8MOLJ+<TDFIGT`X-["]V'=C2BS?Z=6
MK-H;=OO4N^:W[U#6UT\.&!O)68RC.K;>,EQ-*$D@'J;A@6F9^Y6=R4J\6E9N
M6?/9B=F'9S+.Y:;EG2K^4DG2INS'</GRZBAA'P[-X>'7+L8QI8TNJV@I088#
M\G`+"<\SYI72/<7.<222:DDXDDYDDXDG$DDG-5OF_P`K_@<[*,&5:KI55C,6
M"L2\!;J?)*P]QIT[%6FJRR`_GHV?@WB3^-=>'?F3^H1`JA![*HD8Q!`0,(<Z
MWVT,Q<R<59*PM-<B"*$?$O9I]_<Z;>17MHXQW$,C7L<,VO:0YKAW.`/(TH01
M@LIMNHZL6%S0=OZ&Q:P6.=HFKYW;X))0H-<<[&5PH-\I4YSVJI]&6>=)&E68
M*"7Z@#+JD`2"'5NZ1=_<GR:3>O)=;D-8[/JB-?+=\`'0[M;VK)/J)IUOJ0MM
M]:/&UFG:JUSI&-%&PWC:&ZBI4T#GN\^.OM,DP]DK#[[^A_(4P2D?\W@'[K0_
MJ?Z)^/ESL+9'ED=7.`Y+%A:X9KTU#JTWF+(-+Q+CE9K)7C(D^RJ\"DDL1<K0
M[T1/)3KPB1A.2+KL4DN^=''H"H-S=B'QYX[NZBTW39I9ZM-"3V`?A0<S15C0
M=$O]PZQ;:3IS/,NIY&L8WF7',UH`T>TXDX-!*WA<(8AJF!,2T'#]);^A7*%7
M&$$T5.``YD7**?J2<T_$.P/)3DHJL[<&#P%98W0`'0!KQ?WDE_>27<OM/=6G
M(<!\`H%]3=L;?L]K:!:Z#8C\Q;1!M>+G9O>>U[R7'OH*"@6#GN::8Y4W,@-6
MHO%EEHM:<X3VQQ9G*VJ7E2<31DJ=2EGQYB-@?N..D3GL"Y7)?0*N":`^/F.7
MGB-3DJ\I-%$TUDU$E4R*I*D,FJDH4ITU$SE$ITU"&`2G(<HB`@(="')1:]>(
M_:*SQA#>+%.0Z5D/$RFFF%<^9IS;BW'KX;@&3J"PSO1S1=RQ]"IA&JU@(!"W
MMF[AJ'U(=-DP.8?5,<@P!3N7&F/8I(-_=`\>[X8\K,1+66=Q7F#%EA3NV"\Z
MTL`)<L7W)N**A7+42.&2TC`R*C5'ZUD#A`5#()*IJI+))G`152L)82._6",:
MPPX\3D/;^S\5FW1CXK.=P>Y.I%I5;"W202D9RF0,8VAY"78`7SKF*4A'2W8_
M`>Q8]B8J[>J'MN9$K^?_`.6MOCG-KM+MDRA7-=QTG!5\]6PE@&#?&=)R#3$]
M1<&]<\J_:N#)FDG22*Z9%5>B&64.X.`.912*[!X<K^PN#,N8-M!4?N+*^/+7
M1'JZ[8KLC`;%#NX]I*E;'$I%UH=ZLFZ3*(]"HB7ODJ5$][;_`+;^R.OV8X#-
M&WF1L3Y)L.&=5J/J3KTWQHG:U$JW182=D9FSSLTM:8Z-,E89U))@V.=N!RN$
MB'%4"G*43PHHIA,IXOH>:\<W3$N3ZXPMV/L@UZ1J]LKDD4XM92'E$#(.$O42
M,FNV<I"(*(+I&(LW7(15,Q5"%,$J5"'CW3_W8=`VPXTTKS3@/9_6)@[>%QYB
MO;;]]M8ON*XEXHJY2@8W(-*1<!-0,6HKY$$C%23_`,D1NW*(D&,1DHQ7*G/;
M]W]WWGZXE[F^<\45+6Z!GF5H>:A:IMK,A"9`E(IX5Q&Q64<EV;Z::F:TDHD5
M06Z)3B8!$I?14Z7!0G/)*<U-+=<.8OR)BB;P;<J/7IO$EBJ)J)*4)=@DE7E*
MG]"G'(0S9DV!$K!NP:HI@U,@*9VITB'2,0Y"F"5*@^J.AWNE:&BXIV@&SF)<
MS:V(2"[FH8#VYC)XLQCUD^>OWBD'6;_5V[AP,*T,N`_*9HFJ<PF!H0_G5/%"
M,E"[J)T\]SS97:C4+8G<RPZ?X^K>IF0IZYQ-'PDGDBP6*QDL<">(DTE)RPI(
M,$1.9!OY`,;R)@!Q\IA$.,:I3BKB;1:7;W/O<%;;O:?7?6*&<EUSC\&*PV>&
M&09-8G\)Y2?E7R+6H,B)%3/ZK4$3@Z`W95"G)T(#Q0UJH(-5R0K/O\^LT$<G
M^V<*`/F)GI1I6>?,:/!VB,@1$0<^#@[(#@F(^`*"`CX<>+L3%7SSKIGE+)WN
M5:6;C0%EHS'%^NF/,RU2]5N6/.!=Y>3O\!,14$O6"-8]:$49MW$H4SD7+A$Y
M2)F\@&$0#CC53Q6=V7,64S-^+[_A_(D2A.4?)52G*99XQP0ARN(F>8+,')DA
M.4P(O&P+`J@J'SHKD(H40,4!"5*UMZ#[,V]\)7\[U"R;&X94+=M4:/I;C[(D
M*%\+=$L+U_-M;F)(]P0<0R;8\N7`Z<M"-DT%E$A=*MT3&!L4RH1BN-%M&<E<
MEXB2QEC>9?.I27Q]2)63>J`L]D9*J0+Y\[5!,B0*NG;I@JX<*`DF4OF.81\I
M0#X`'/=%JFIP,$4-Q.R-N0;(\`=P!H%;%YLG9FH73[[4-(TR>]D-7R26L#WO
M.57/=&7.-.))7`'#V)!\!Q;CD0'X@-(K/C_O9SO_`'[K?]<N_P#[2?67F_R\
MV!_<>C_L5M^C42GO':W/K#@2BY8H*"[.%UTEY64L./X)!-E71I5L3;L9VULH
M-BDFU)+U-TFDX.<I`$(]9V;OL.C77LS6WMU"2WNSYD]R6GS'DN<7,!P+C4D=
M.5>(HL)>\#L)LFT[;4]`8V#3]+#FFVB:UD+8YG-)E9&P-:US7@!U!BUQ-,"3
MKA(B0Y2G24\Z9B@8.O$HE$.RF`?@("'VAS,,CPZCR,'#!:+T+30YA5^=>"E<
M99RFS16>+'*5!$IE#J&-T4A"%\QC&$?`"E`O8CSE-&9XF0-P>W$J&CQ]ZV9/
M:IU,9P6J;F>S768ZV-L\7%OEZ(QS>X6/L-;JL,E$IPU/F&U<G6;QE'V:PPA/
MKG+@I`5%%PBF/0IF[PQO/5A-JPALW%A@9T.<TD5/5U$5!Q#32OT@>55OWZ#;
M$%ILDW6XH8YX;Z<3Q0S1M>UC&L,;9>EX(#Y07$$"OE%N/B($C7\F'6KKK^3S
M@WKX]?HEH/7?X>ON#EK-U75&&K;FX![)'_TK-'\H;3.>EZ=^S0_47?5?!>$J
M1-M[+2\.XKJ%C:H.6S6P5?'M2@)MLV>)@D[;MY6*B&C]%!TD'E4(50"G+X&`
M0YURW]].TLGFE>PYASW$'CB">>*]5GM[0-/F%S86-G!<-K1\<,;'"HH:.:T$
M5!(..(-%=3GD583A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A%ULS#QEAAY6`FV+>3AIR-?0\O&O$RK-)",DVJK)^Q=(G`2*MW;1<Z9R
MCX&*80'G..1\4C98S21I!!Y$&H*\]W:V]]:2V-TT/M9HW,>TY.8\%K@>P@D%
M:1.U.#U=1L_WC"4](%2@F2Q;+C&7DEB(FG\:3BRRD`J"JHE!R]@3IJ1;P0['
MZEH8P^!RB.P6W=7@U/2FR&GFCAR(S'P'+L(7S!]1MEWFR]U7&C/#G0,=U1OI
M[<3JF-_'$C!V.#VN"L)^^.O"'7W]%?9_J]M^7O\`.<K(>`:](5A^5+\TK*C2
M77]OMYL?4,8D.D_Q_6S(W[+KMDJ5=NE2H5XB*->771,8$G-UEO2CR%$?,+<S
MA0`Z3'E`W+JYTG37WD3P9GCH`X]1K3XJ$GL';0Y*]*MCS;VW=;Z9(QW[O8[S
M)W9=,+,78\WFD;:8U?44`+F[JC9LW9-F[-H@BU:-$$FS5LW3(BW;MT$RI(((
M(I@5-)%%,H%*4H`!2@`!X<P"YSGN+G&KB:D\ROII##%;Q-@@:&0L:&M:!0-:
M!0`#@`!0#DJ_(78G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G"*.O<_\`CG2?[W;_`!9DOYYO\=/]U"?Q)_YL_P"N?]E=<KVD
M_9G]?]O_`*'LY#/Z7Y*+&.^/XC%_AG[#^TOMO:=['_BY?3ZEAX7XA_>+/R?'
ME:.7]MJR!G_^`6<FE7^F,E?S#O\`BO\`S*_V_P#83/\`VD?\%_B^IY0M5^S9
M^N^T?M\O^7MY_`K^V-^L7'^'?89_#?:X_:_1^;VU6>?*(LCIPB<(G")PB<(G
@")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
